1. Scrip
  2. >>Business

Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Covers Novel Cancer Immunotherapy Targets And Therapies

 
• By Andrew McConaghie

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

Cancer cell and T cells
'Dark antigens' are hidden targets for immunotherapies which could be revealed thanks to new drug discovery techniques

Boehringer Ingelheim has signed a deal with Enara Bio to explore the potential of what the UK biotech calls ‘dark antigens’ – antigens derived from the genomic ‘dark matter’ or the 98% of the genome that is not normally expressed, but which could yield many new targets for cancer immunotherapies.

The collaboration will focus on the discovery and validation of up to three dark antigens for lung and gastrointestinal cancers, with Enara eligible to receive more than €876m ($1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.